Abstract
Idiopathic hypersomnia (IH) is a rare slee** disorder that is difficult to diagnose, and little is known about its pathophysiology. A defining symptom of IH is excessive daytime sleepiness, which can manifest as narcolepsy-like episodes or as continuous sleepiness. Other symptoms of IH includes sleep inertia and cognitive impairment. Currently, calcium, magnesium, potassium and sodium oxybates is the only FDA approved pharmacological treatment option in the management of IH. Off-label treatment options are recommended by guidelines, with many also being used for the management of narcolepsy.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Arnulf I, Thomas R, Roy A, et al. Update on the treatment of idiopathic hypersomnia: progress, challenges, and expert opinion. Sleep Med Rev. 2023;69:101766.
Morse AM, Naik S. Idiopathic hypersomnia: neurobiology, diagnosis, and management. CNS Drugs. 2023;37(4):305–22.
Maski K, Trotti LM, Kotagal S, et al. Treatment of central disorders of hypersomnolence: an American Academy of Sleep Medicine clinical practice guideline. J Clin Sleep Med. 2021;17(9):1881–93.
Tanida K, Shimada M, Khor SS, et al. Genome-wide association study of idiopathic hypersomnia in a Japanese population. Sleep Biol Rhythms. 2022;20:137–48.
Neikrug AB, Crawford MR, Ong JC. Behavioral sleep medicine services for hypersomnia disorders: a survey study. Behav Sleep Med. 2017;15(2):158–71.
Avadel CNS Pharmaceuticals LLC. Sodium oxybate for extended-release oral suspension: US prescribing information. 2023. https://dailymed.nlm.nih.gov/. Accessed 12 Sep 2023.
Ajanta Pharma USA Inc. Clarithromycin: US prescribing information. 2023. https://dailymed.nlm.nih.gov/. Accessed 5 Jul 2023.
Amneal Pharmaceuticals of New York LLC. Dexmethylphenidate hydrochloride: US prescribing information. 2022. https://dailymed.nlm.nih.gov/. Accessed 5 Jul 2023.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Funding
The preparation of this review was not supported by any external funding.
Authorship and conflict of interest
A Lee is a salaried employee of Adis International Ltd/Springer Nature and declares no relevant conflicts of interest. All authors contributed to this article and are responsible for its content.
Ethics approval, Consent to participate, Consent for publication, Availability of data and material, Code availability
Not applicable.
Rights and permissions
Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
Lee, A. Manage idiopathic hypersomnia with a combination of non-pharmacological and pharmacological treatments. Drugs Ther Perspect 39, 378–381 (2023). https://doi.org/10.1007/s40267-023-01028-7
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40267-023-01028-7